ADPT — Adaptive Biotechnologies Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1478320 ·
Last close
$22.56
Market Cap
$3.59B
52W High
$23.15
52W Low
$12.50
ADV30
3,491,013
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 70,874,000 | 52,166,000 | -19,206,000 | -20,033,000 | 505,943,000 | 77,581,000 | 281,702,000 |
| Dec 2025 | 71,681,000 | 53,457,000 | -12,773,000 | -13,579,000 | 512,736,000 | 70,495,000 | 287,735,000 |
| Sep 2025 | 93,973,000 | 75,816,000 | 10,290,000 | 9,546,000 | 490,610,000 | 55,034,000 | 286,357,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,986,000
Investing CF
$37,950,000
Financing CF
$30,403,000
CapEx
$-2,959,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.40
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,363,323,000
Inventory
$9,820,000
Receivables
$50,365,000
ST Investments
$156,485,000
EBIT TTM
$-47,679,000
Pretax Income TTM
$-59,457,000
Interest Exp TTM
$11,778,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$308,080,992
EBITDA
$-21,185,000
Free Cash Flow
$16,102,625
Enterprise Value
$3,920,053,760
Total Cash
$344,255,008
Total Debt
$410,499,008
Shares Out
159,059,622
Trailing EPS
$-0.40
Book Value
$1.42
ROE
-38.8%
ROA
-4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 276,976,000 | -57,123,000 | -59,499,000 | 512,736,000 | 287,735,000 | — | -45,986,000 |
| Dec 2024 | 178,957,000 | -155,344,000 | -159,492,000 | 539,376,000 | 336,891,000 | — | -95,212,000 |
| Dec 2023 | 170,276,000 | -201,606,000 | -225,250,000 | 661,134,000 | 352,856,000 | — | -156,324,000 |
| Dec 2022 | 185,308,000 | -200,186,000 | -200,191,000 | 856,617,000 | 392,519,000 | — | -183,945,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.22
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | $3.79B | $23.85 | — |
| RLAY | Relay Therapeutics, Inc. | $4.00B | $18.37 | — |
| CRSP | CRISPR Therapeutics AG | $4.69B | $47.64 | — |
| BEAM | Beam Therapeutics Inc. | $2.68B | $26.02 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.55B | $58.52 | — |
News headlines (Yahoo Finance, 1h cache)
Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...
2026-07-30 05:03 · Yahoo
Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say
2026-07-29 23:00 · Yahoo
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
2026-07-29 22:25 · Yahoo
Adaptive Biotechnologies Q2 Earnings Call Highlights
2026-07-29 22:03 · Yahoo
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
2026-07-29 20:05 · Yahoo
Adaptive Biotechnologies (ADPT) After Loss Forecasts Improve Is The Rally Already Priced In
2026-07-24 12:11 · Yahoo
Adaptive Biotechnologies (ADPT) Stock May Be 22% Undervalued As Growth Hopes Build
2026-07-24 08:10 · Yahoo
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2026-07-23 14:00 · Yahoo
Will Earnings Estimate Upgrades and a Smaller Projected Loss Change Adaptive Biotechnologies' (ADPT) Narrative?
2026-07-23 05:11 · Yahoo
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2026-07-22 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.